Literature DB >> 9066636

Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro.

M Volm1, R Koomägi, J Mattern, G Stammler.   

Abstract

Tumor specimens of non-small cell lung carcinomas (NSCLC) from previously untreated patients (n = 153) were analysed immunohistochemically for expression of vascular endothelial growth factor (VEGF), VEGF-receptor (Flt-1), basic fibroblast growth factor (bFGF) and FGF-receptor (FGFR-1, (Flg). Expression of the proteins was compared with the in vitro response of the tumors against doxorubicin. The data clearly demonstrate that a significant relationship exists between VEGF (p < 0.001) and Flt-1 expression (p < 0.01) and drug response. The expression of VEGF and Flt-1 was lower in resistant than in sensitive tumors. In contrast, no significant interrelationship was found between expression of bFGF and response to doxorubicin. However, there exists a significant correlation between the expression of FGF-receptor (FGFR-1) and the response of the carcinomas to doxorubicin (p < 0.05). Expression of FGFR-1 was more frequently negative or weak in resistant and more frequently moderate or high in sensitive NSCLC. The data from this investigation clearly demonstrate that a significant interrelationship exists between the expression of VEGF, VEGF-receptor Flt-1 and FGF-receptor, FGFR-1 and the response of NSCLC to doxorubicin in vitro.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9066636

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  RLIP76 regulates HIF-1 activity, VEGF expression and secretion in tumor cells, and secretome transactivation of endothelial cells.

Authors:  Seunghyung Lee; Lawrence E Goldfinger
Journal:  FASEB J       Date:  2014-06-13       Impact factor: 5.191

2.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

Authors:  K L van Golen; Z F Wu; X T Qiao; L Bao; S D Merajver
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

3.  Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference.

Authors:  Shaochuang Wang; Hui Liu; Lifeng Ren; Yifeng Pan; Yangde Zhang
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

Review 4.  Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.

Authors:  Samar Masoumi Moghaddam; Afshin Amini; David L Morris; Mohammad H Pourgholami
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

5.  Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.

Authors:  Y Shou; T Hirano; Y Gong; Y Kato; K Yoshida; T Ohira; N Ikeda; C Konaka; Y Ebihara; F Zhao; H Kato
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

6.  Expression of vascular endothelial growth factor in oral squamous cell carcinoma.

Authors:  Seok-Kon Kim; Seung-Goo Park; Kyung-Wook Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2015-02-24

7.  Serum vascular endothelial growth factor levels in patients with non-small cell lung cancer.

Authors:  Ahmet Demirkazik; Hakan Akbulut; A Fusun Ulger; Ali Arican; Ismail Ozer; Nalan Acikgoz; Fikri Icli
Journal:  Ann Saudi Med       Date:  2004 Nov-Dec       Impact factor: 1.526

Review 8.  Are we causing the recurrence-impact of perioperative period on long-term cancer prognosis: Review of current evidence and practice.

Authors:  Jyotirmoy Das; Sudhir Kumar; Sangeeta Khanna; Yatin Mehta
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.